Literature DB >> 11912002

Cognitive impairment correlates with hypothalamo-pituitary-adrenal axis dysregulation in multiple sclerosis.

Christoph Heesen1, Stefan M Gold, Alaleh Raji, Klaus Wiedemann, Karl-Heinz Schulz.   

Abstract

Hypothalamo-pituitary-adrenal (HPA) dysregulation has recently been demonstrated in multiple sclerosis (MS) by means of combined dexamethasone corticotropin-releasing hormone (Dex-CRH) suppression tests. Authors found a correlation with course of disease and to a lesser extent with depressive symptoms. In this study, we aimed to further evaluate whether HPA disturbances in MS are correlated with cognitive impairment, disability status, and fatigue. Dex-CRH tests were performed in a total of 40 patients and 11 healthy controls. Concomitantly, cognitive impairment was evaluated using the symbol digit modalities test and fatigue was assessed by different fatigue severity scales. When comparing patient subpopulations to healthy subjects, Dex-CRH stimulation tests indicated an HPA hyperactivity in primary and secondary progressive MS, while relapsing-remitting patients had response patterns similar to controls. However, results were only significant for one of the six analysed parameters, i.e. area under the curve calculations of ACTH stimulation. Within the patient sample, clear-cut differences emerged between groups of different cognitive impairment, being significant for all ACTH response parameters. Our results suggest an HPA hyperactivation related to increased cognitive impairment. Indicators of HPA axis activation further correlated substantially with neurologic disability, but only moderately with duration of disease and even less with depressive symptoms and fatigue. We conclude that the observed dysregulation is more likely a secondary effect of the extent of brain damage rather than primarily involved in the pathogenesis of MS.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11912002     DOI: 10.1016/s0306-4530(01)00071-3

Source DB:  PubMed          Journal:  Psychoneuroendocrinology        ISSN: 0306-4530            Impact factor:   4.905


  15 in total

1.  Fatigue in multiple sclerosis: an example of cytokine mediated sickness behaviour?

Authors:  C Heesen; L Nawrath; C Reich; N Bauer; K-H Schulz; S M Gold
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-01       Impact factor: 10.154

2.  Biological outcome measurements for behavioral interventions in multiple sclerosis.

Authors:  Anja Fischer; Christoph Heesen; Stefan M Gold
Journal:  Ther Adv Neurol Disord       Date:  2011-07       Impact factor: 6.570

Review 3.  Possible mechanisms of the formation of chronic fatigue syndrome in the clinical picture of multiple sclerosis.

Authors:  D S Kasatkin; N N Spirin
Journal:  Neurosci Behav Physiol       Date:  2007-03

4.  Sleep disturbance and cognitive decline in multiple sclerosis patients with isolated optic neuritis as the first demyelinating event.

Authors:  Recai Türkoğlu; Gülçin Benbir; Selen Özyurt; Erdil Arsoy; Ece Akbayır; Selin Turan; Derya Karadeniz; Vuslat Yılmaz; Mehmet Gencer; Erdem Tüzün
Journal:  Int Ophthalmol       Date:  2019-08-20       Impact factor: 2.031

5.  Evidence for cognitive impairment in mastocytosis: prevalence, features and correlations to depression.

Authors:  Daniela Silva Moura; Serge Sultan; Sophie Georgin-Lavialle; Stéphane Barete; Olivier Lortholary; Raphael Gaillard; Olivier Hermine
Journal:  PLoS One       Date:  2012-06-20       Impact factor: 3.240

6.  Adverse Childhood Experiences Are Linked to Age of Onset and Reading Recognition in Multiple Sclerosis.

Authors:  Michael T Shaw; Natalie O Pawlak; Ariana Frontario; Kathleen Sherman; Lauren B Krupp; Leigh E Charvet
Journal:  Front Neurol       Date:  2017-06-02       Impact factor: 4.003

Review 7.  Is there a link between inflammation and fatigue in multiple sclerosis?

Authors:  Moussa A Chalah; Samar S Ayache
Journal:  J Inflamm Res       Date:  2018-06-07

8.  Multiple sclerosis, relapses, and the mechanism of action of adrenocorticotropic hormone.

Authors:  Amy Perrin Ross; Aliza Ben-Zacharia; Colleen Harris; Jennifer Smrtka
Journal:  Front Neurol       Date:  2013-03-08       Impact factor: 4.003

Review 9.  Neurobehavioral burden of multiple sclerosis with nanotheranostics.

Authors:  Bhasker Sriramoju; Rupinder K Kanwar; Jagat R Kanwar
Journal:  Neuropsychiatr Dis Treat       Date:  2015-10-15       Impact factor: 2.570

10.  Stress-Axis Regulation by Vitamin D3 in Multiple Sclerosis.

Authors:  Linda Rolf; Jan Damoiseaux; Inge Huitinga; Dorien Kimenai; Jody van den Ouweland; Raymond Hupperts; Joost Smolders
Journal:  Front Neurol       Date:  2018-04-26       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.